JP2014198718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014198718A5 JP2014198718A5 JP2014109910A JP2014109910A JP2014198718A5 JP 2014198718 A5 JP2014198718 A5 JP 2014198718A5 JP 2014109910 A JP2014109910 A JP 2014109910A JP 2014109910 A JP2014109910 A JP 2014109910A JP 2014198718 A5 JP2014198718 A5 JP 2014198718A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibition
- activity
- pde7a
- pde7b
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims 23
- 230000005764 inhibitory process Effects 0.000 claims 21
- 208000016285 Movement disease Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 claims 9
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 claims 9
- 101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims 9
- 102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 210000000653 nervous system Anatomy 0.000 claims 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 3
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 3
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 3
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 2
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 claims 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 claims 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 101150098694 PDE5A gene Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101710122057 Phospholemman-like protein Proteins 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 210000001640 nerve ending Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92049607P | 2007-03-27 | 2007-03-27 | |
| US60/920,496 | 2007-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Division JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014198718A JP2014198718A (ja) | 2014-10-23 |
| JP2014198718A5 true JP2014198718A5 (enExample) | 2015-03-26 |
| JP5943964B2 JP5943964B2 (ja) | 2016-07-05 |
Family
ID=39789284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Active JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
| JP2014109910A Active JP5943964B2 (ja) | 2007-03-27 | 2014-05-28 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Active JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20080260643A1 (enExample) |
| EP (1) | EP2139475B1 (enExample) |
| JP (2) | JP5580192B2 (enExample) |
| CN (2) | CN101917992A (enExample) |
| AU (1) | AU2008230710B2 (enExample) |
| CA (1) | CA2681650C (enExample) |
| ES (1) | ES2533206T3 (enExample) |
| MX (1) | MX2009010450A (enExample) |
| NZ (1) | NZ580413A (enExample) |
| RU (1) | RU2449790C2 (enExample) |
| WO (1) | WO2008119057A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
| FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
| FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
| AU2013202493B2 (en) * | 2009-05-04 | 2016-03-10 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| ES2360783B1 (es) | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| MX2013004943A (es) | 2010-11-08 | 2013-09-02 | Omeros Corp | Tratamiento de trastornos de adicion y control de impulsos usando inhibidores de pde7. |
| HRP20190279T1 (hr) * | 2012-05-07 | 2019-04-05 | Omeros Corporation | Liječenje ovisnosti i poremećaja nagona pomoću pde7 inhibitora |
| EP2846805B1 (en) * | 2012-05-07 | 2018-11-21 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| US20190185479A1 (en) * | 2016-08-26 | 2019-06-20 | Mitsubishi Tanabe Pharma Corporation | Bicyclic nitrogenated heterocyclic compound |
| JP2021535180A (ja) * | 2018-09-05 | 2021-12-16 | ユニベルシテイト ファン アムステルダム | パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用 |
| CA3264002A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITING ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE |
| WO2024259383A2 (en) * | 2023-06-14 | 2024-12-19 | President And Fellows Of Harvard College | Ion channel binders and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| DE3852539T3 (de) | 1987-12-15 | 2005-08-04 | Gene Shears Pty. Ltd. | Ribozyme. |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
| WO1999042596A2 (en) * | 1998-02-23 | 1999-08-26 | Icos Corporation | Phosphodiesterase 10 |
| DK1018559T3 (da) * | 1998-12-23 | 2007-12-03 | Pfizer | Phosphodiesteraser |
| AU4589800A (en) | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
| WO2000068203A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
| DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
| US7491742B2 (en) * | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
| DE19953025A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
| DE19953024A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953414A1 (de) * | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
| DE19954707A1 (de) * | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| KR20020097182A (ko) * | 2000-02-22 | 2002-12-31 | 셀러지 캐나다 인크. | 수면을 개선시키는 방법 및 조성물 |
| AU4415501A (en) | 2000-02-24 | 2001-09-03 | Bayer Aktiengesellschaft | Regulation of human gelatinase b-like enzyme 1 |
| GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
| GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
| MXPA03001717A (es) | 2000-08-30 | 2003-09-22 | Lilly Icos Llc | METODO PARA EL TRATAMIENTO DE LA MIGRAnA. |
| EP1193261A1 (en) | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| WO2002040449A1 (en) | 2000-11-14 | 2002-05-23 | Altana Pharma Ag | Dihydroisoquinolines as novel phosphodiesterase inhibitors |
| CZ20031334A3 (cs) | 2000-11-14 | 2003-09-17 | Altana Pharma Ag | Isochinolinové deriváty a jejich použití jako inhibitory |
| IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
| HUP0600103A2 (en) * | 2001-03-02 | 2006-06-28 | Bristol Myers Squibb Co | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| US6617357B2 (en) * | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
| AP1699A (en) * | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
| JP2004532228A (ja) | 2001-04-18 | 2004-10-21 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Ｐｄｅ阻害作用をもつアリールインデノピリジン |
| US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| PL363312A1 (en) | 2001-04-25 | 2004-11-15 | Altana Pharma Ag | Novel phthalazinones |
| US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
| US6849638B2 (en) * | 2001-04-30 | 2005-02-01 | Bayer Pharmaceuticals Corporation | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| BR0210030A (pt) * | 2001-06-15 | 2004-08-10 | Yamanouchi Pharma Co Ltd | Derivado de fenilpiridinacarbonilpiperazina |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| HUP0402352A2 (hu) * | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| DE10130167A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| KR20040066788A (ko) * | 2001-08-31 | 2004-07-27 | 더 락커펠러 유니버시티 | 프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절 |
| US20060286622A1 (en) * | 2001-09-28 | 2006-12-21 | Patricia Soulard | Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| CA2439784C (en) * | 2001-12-13 | 2010-11-02 | Daiichi Suntory Pharma Co., Ltd. | Pyrazolopyrimidinone derivatives having pde7 inhibiting action |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| WO2003064389A1 (en) * | 2002-01-31 | 2003-08-07 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient |
| US20040082061A1 (en) * | 2002-02-14 | 2004-04-29 | Anna Astromoff | Drug metabolizing enzymes |
| EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
| EP1348433A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2004044196A1 (en) | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| US7217527B2 (en) * | 2003-04-15 | 2007-05-15 | Vanderbilt University | Assay for phosphodiesterase function |
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| WO2005018563A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| PT1775298E (pt) | 2004-07-01 | 2013-06-12 | Daiichi Sankyo Co Ltd | Derivado de tienopirazol com atividade inibidora da pde 7 |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| WO2006092691A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| WO2007047978A2 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006321349A1 (en) * | 2005-12-02 | 2007-06-07 | Pfizer Limited | Spirocyclic quinazoline derivatives as PDE7 inhibitors |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
-
2008
- 2008-03-27 NZ NZ580413A patent/NZ580413A/xx unknown
- 2008-03-27 CN CN200880017058XA patent/CN101917992A/zh active Pending
- 2008-03-27 RU RU2009138966/15A patent/RU2449790C2/ru active
- 2008-03-27 CN CN201510082785.6A patent/CN104758291B/zh active Active
- 2008-03-27 JP JP2010501232A patent/JP5580192B2/ja active Active
- 2008-03-27 EP EP08744515.1A patent/EP2139475B1/en active Active
- 2008-03-27 MX MX2009010450A patent/MX2009010450A/es active IP Right Grant
- 2008-03-27 AU AU2008230710A patent/AU2008230710B2/en active Active
- 2008-03-27 WO PCT/US2008/058530 patent/WO2008119057A2/en not_active Ceased
- 2008-03-27 US US12/057,368 patent/US20080260643A1/en not_active Abandoned
- 2008-03-27 CA CA2681650A patent/CA2681650C/en active Active
- 2008-03-27 ES ES08744515.1T patent/ES2533206T3/es active Active
-
2010
- 2010-12-21 US US12/974,693 patent/US20110091388A1/en not_active Abandoned
-
2014
- 2014-05-28 JP JP2014109910A patent/JP5943964B2/ja active Active
-
2018
- 2018-12-06 US US16/212,064 patent/US20190183824A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014198718A5 (enExample) | ||
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| RU2449790C2 (ru) | Использование ингибиторов pde7 для лечения нарушений движения | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| BR112014017626A2 (pt) | métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio | |
| EP2911695C0 (en) | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE BY SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC TYPES OF NEURONS | |
| EP3207931A3 (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies | |
| EA201591290A2 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| BR112012028136A2 (pt) | terapia de combinaçao | |
| EA201390070A1 (ru) | Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина | |
| BR112015029090A2 (pt) | compostos de 3,4-di-hidroisoquinolin-2(1h)-ila | |
| EP2844256A4 (en) | TREATMENT OF NEURONAL DISEASES WITH TYROSINE CHINESE INHIBITORS | |
| Ide et al. | Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201170043A1 (ru) | Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений | |
| JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| WO2013049725A3 (en) | Methods of using adenosine a1 receptor activation for treating depression | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| BR112017005533A2 (pt) | compostos e métodos | |
| MY164007A (en) | Quinolone compound and pharmaceutical composition | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| BR112014028446A2 (pt) | composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo | |
| FR3000896B1 (fr) | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil | |
| MA34106B1 (fr) | Combinaison de composés organiques |